{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-007928","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.242019+00:00","generated_at":"2026-06-05T11:28:04.316853+00:00","sec_items":["1.01","2.03","3.02","5.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Qualigen issues $550K 8% convertible debenture, warrants; CMO resigns","bullets":["Issued $550,000 principal 8% Convertible Debenture to Alpha Capital for $500,000 cash; due Dec 31, 2024; convertible at $0.6111/sh.","Issued 5-year warrant to Alpha for 900,016 shares at $0.26/sh; triggers ratchet anti-dilution adjustments on existing instruments.","Alpha has option to purchase additional $1.1M debentures plus 1.8M warrants for $1M cash, exercisable until July 1, 2024.","Ratchet adjustments: existing Alpha debenture convertible into 4.6M shares (from 1.6M); Series C warrants become exercisable for 1.28M shares at $0.26.","Tariq Arshad resigned as SVP/Chief Medical Officer effective February 25, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-007928","json":"https://secwatch.observer/filing/0001493152-24-007928.json","markdown":"https://secwatch.observer/filing/0001493152-24-007928.md","text":"https://secwatch.observer/filing/0001493152-24-007928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315224007928/0001493152-24-007928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315224007928/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:28:04.316853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"269365f116","claim":"Tariq Arshad resigned as Senior Vice President/Chief Medical Officer at AIxCrypto Holdings, Inc..","evidence_excerpt":"On February 25, 2024, Tariq Arshad resigned from his position as the Company’s Senior Vice President/Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315224007928/0001493152-24-007928-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President/Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"ce11b6726dcedf8c49ba23fa6c1406bb40804be7","claim":"AIxCrypto Holdings, Inc. entered into Securities Purchase Agreement with Alpha Capital Anstalt valued at $500,000 (effective 2024-02-26).","evidence_excerpt":"On February 26, 2024, Qualigen Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“Agreement”) with Alpha Capital Anstalt (“Alpha”). The transactions contemplated by the Agreement are expected to close on February 27, 2024, at which time the Company would deliver to Alpha the Debenture and the Warrant, as described below, and Alpha would pay the Company a cash purchase price of $500,000 (less expenses).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315224007928/0001493152-24-007928-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Alpha Capital Anstalt"},{"label":"Value","value":"$500,000"},{"label":"Effective","value":"2024-02-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}